Why do some people seem to be resistant to skin cancer, while many of us (who regularly visit SkinCancer.org) seem prone to it? Turns out there’s a gene that’s at least partially responsible, according to a 2016 study.
Why do some people seem to be resistant to skin cancer, while many of us (who regularly visit SkinCancer.org) seem prone to it? Turns out there’s a gene that’s at least partially responsible, according to a 2016 study.
Wrinkles, fine lines and pigmentation are inevitable skin woes that often appear as we age. While we like to place blame on getting another year older, the main culprit is photoaging — damage to the skin caused by exposure to sunlight and ultraviolet (UV) light. Responsible for 90 percent of visible changes to the skin, photoaging is a direct result of cumulative sun damage you’ve been exposed to throughout your life.
Photosensitivity occurs when the skin reacts in an abnormally sensitive way to light from the sun or an artificial source of ultraviolet (UV) radiation, like a tanning bed.
We saw the FDA approve a groundbreaking drug, companies debut new technology to help increase our awareness of dangerous ultraviolet (UV) rays and lawmakers pass indoor tanning legislation.
The last thing Summer Sanders expected to hear at a routine visit to her dermatologist was the word “melanoma.”
All melanomas are associated with an initial tumor, but sometimes the location is difficult to ascertain.
On the evening of October 25, the Grand Ballroom at The Plaza in New York City was buzzing with excitement. […]
While skin cancers are less commonly diagnosed in areas that are normally shielded from the sun, they can and do develop there.
As we get ready to announce our 2018 Media Award winner, we caught up with past recipient Jenna Rosenstein, who won for her article highlighting indoor tanning on campuses. Two years later, the impact of the article is still reverberating and remains an important topic of conversation.
You may have heard about a new medication that was recently FDA approved for cutaneous squamous cell carcinoma (CSCC). Libtayo (cemiplimab-rwlc) is a type of immunotherapy called a checkpoint blockade inhibitor, and it’s the first one approved to treat certain cases of CSCC. This is exciting news, so let’s break down how this new drug works and whom it might help.
English
Chinese (Simplified)
French
German
Italian
Portuguese
Spanish